Testing times: how medtech firms can get the most from the annual business review
This article was originally published in Clinica
Executive Summary
Most medtech companies find the annual business plan review an unsatisfactory process. Research into those few who do find the process beneficial reveal three valuable lessons, writes Prof Brian Smith
You may also be interested in...
Life Science’s Tangled Bank Of Business Models
The pharma industry is experiencing an explosion of new business models, more numerous and specialized than we're used to. Companies need to pick the right model and adapt faster and better than their competitors. Part 3 in a series from Brian Smith's new book, Darwin's Medicine.
Six Big Shifts In Life Sciences
Where is our industry headed? Exactly where it is being pushed by what Charles Darwin called "immeasurably superior forces." Part 2 in a series from Brian Smith's new book, Darwin's Medicine.
Where Do Life Science Business Models Come From?
In his forthcoming book, Darwin’s Medicine, Brian Smith argues that the emergence of new business models in the life science industry is explained by Darwin’s brilliant idea.